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from acute infectious episodes to chronic
inflammatory diseases. The plasticity in
their phenotypic fates allows for shaping
of their functional repertoire by the specific
nature of the pathogenic stimulus present.
As the principal site of CCR2 control of the
inflammatorymonocyte pool is at the point
of their release from the bone marrow
(Dunay et al., 2008), the key question of
what alternative chemokine signals are
evoked by pathogens to recruit and mobi-
lize inflammatory monocytes remains. A
recent study demonstrated that systemic
induction of IFN-g during Listeria infection
remotely induced the expression of the
chemokines CXCL9 and CXCL10 (Drevets
et al., 2008), which presumably resulted in
CCR2-independent recruitment of mono-
cytes into the brain even before bacterial
colonization of the central nervous system
(CNS) occurred. Thus, Toxoplasma and
other neuroinvasive pathogens could be
subverting the innate cytokine response
by using inflammatory monocytes to ferry
themselves around and gain entry into the
brain to establish latent infection (Courret
et al., 2006; seeFigure 1, arrow#3). Inflam-
matory monocytes also likely differentiate
into perivascularmicroglial cells andmedi-
ate iNOS-dependent control of parasite
replication in the brain (Benevides et al.,
2008). By inducing robust Th1 and inflam-
matory monocytic responses, pathogens
could simultaneously increase the proba-
bility that their host organisms survive
acute infection, enhance their owndissem-
ination, and provide themselves a stable
chronic niche. Alas, the parasite seems to
always get the last laugh.
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The antiherpes drug acyclovir was found to inhibit HIV following its phosphorylation by human herpesviruses,
providing a hypothesis to explain the observed beneficial effects of acyclovir therapy on HIV viral load and
HIV disease progression. This report underscores the importance of studying HIV in the context of microbial
copathogens.HIV infection has been shown to worsen
the course of infection by many patho-
genic microbes and may lead to clinical
illness from infection by relatively non-
pathogenic or commensal organisms
(reviewed in USPHS/IDSA Prevention of
Opportunistic Infections Working Group,
1997; Sulkowski et al., 2000). While
many of these interactions appear to be
due to immune suppression, some infec-
tions are worsened in people with pre-194 Cell Host & Microbe 4, September 11, 2served CD4 counts, suggesting a direct
effect of HIV on the coinfecting microbe.
The opposite effect has also been ob-
served both in vivo and in vitro: Infection
by a number of organisms is associated
with inhibition of HIV replication and de-
layed HIV disease progression, which
may be mediated by direct or indirect
interactions (Stapleton et al., 2004). For
example, HIV-induced depletion of CD4+
T lymphocytes is thought to be driven by008 ª2008 Elsevier Inc.host immune activation, which occurs at
least in part as a result of coinfecting
microbial infection (Douek, 2003). In this
issue of Cell Host & Microbe, studies by
Lisco and colleagues in the Margolis lab-
oratory at the National Institutes of Health
identify an unexpected type of microbial
interaction that may influence HIV disease
(Lisco et al., 2008), further illustrating the
complex interplay between microbial in-
fections within their hosts.
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PreviewsInteractions between HIV and human
herpesviruses were recognized early in
the AIDS epidemic. HIV infection greatly
increased the likelihood of herpesvirus
reactivation disease from herpes simplex
virus (HSV) -1 and -2, varicella zoster virus
(VZV), Epstein-Barr virus (EBV), cytomeg-
alovirus (CMV), and human herpesvirus
6 (HHV-6) (USPHS/IDSA Prevention of
Opportunistic Infections Working Group,
1997). Prophylactic therapy with acyclovir
decreased the frequency of HSV-2 reac-
tivation in HIV-infected people, and
surprisingly, some studies found that this
therapy was associated with lower
plasma HIV RNA levels and delayed HIV-
related mortality (reviewed in Corey,
2007). Since acyclovir has not previously
demonstrated anti-HIV activity in vitro, it
has been assumed that any acyclovir ef-
fect must occur as a result of decreasing
HSV replication and host immune activa-
tion (Corey, 2007).
Acyclovir is an acylic nucleoside analog
that requires phosphorylation to be an ac-
tive inhibitor of herpesvirus DNA polymer-
ase (Balfour, 1984). Part of the specificity
for acyclovir is the requirement of initial
phosphorylation by a herpesvirus thymi-
dine kinase (Balfour, 1984). Since this
kinase is largely restricted to herpesvi-
rus-infected cells, the drug has limited
toxicity in uninfected cells. Acyclovir
phosphorylation varies widely among
human herpesviruses, and the activity of
acyclovir correlates to some extent with
the efficiency of phosphorylation by these
viruses. Once acyclovir is monophos-
phorylated, the di- and triphosphate forms
are readily generated by cellular kinases,
leading to the active form of the drug
(Balfour, 1984).
The study by Lisco et al. (2008) con-
firms that acyclovir is not active against
HIV in isolated HIV cell-culture systems;
however, they demonstrate that syntheti-
cally monophosphorylated acyclovir, fol-
lowing intracellular conversion to acyclo-
vir triphosphate, inhibits HIV replication.Acyclovir triphosphate interferes with the
HIV RNA-dependent, DNA polymerase
(reverse transcriptase), which results in
DNA elongation termination (Lisco et al.,
2008). This result followed observations
that acyclovir inhibited HIV replication in
lymphoid tissue cultures obtained from
26 of 27 human donors, and also in cervi-
cal-vaginal and rectosigmoid tissue cul-
tures. Inspection of the lymphoid tissues
demonstrated the presence of ubiquitous
human herpesviruses (EBV, CMV, HHV-6,
and HHV-7) in all of the samples except
the one in which acyclovir did not demon-
strate anti-HIV activity. Consistent with
a causal link between this anti-HIV activity
and herpesvirus coinfection, acyclovir ac-
quired anti-HIV activity when incubated
with a CD4+ T cell line coinfected with
HSV-2 and HIV (Lisco et al., 2008). These
results suggest that endogenous herpes-
viruses may phosphorylate acyclovir,
leading to the form of the drug that is ac-
tive against HIV. Since herpesviruses are
ubiquitous in humans, and because HIV
viral load is a predictor of HIV disease pro-
gression and HIV transmission, beneficial
associations between acyclovir and HIV
disease may relate to a direct antiretrovi-
ral effect of the drug.
These results illustrate the importance
of studying microbial infections in the
context of coinfectingmicrobes, and raise
the possibility of exploitingmicrobial coin-
fections to develop novel approaches to
HIV treatment. Lisco and colleagues only
identified the acquisition of anti-HIV activ-
ity by acyclovir, because their studies
were conducted using a lymphoid tissue
culture system to study HIV replication
(Glushakova et al., 1999). Acyclovir phos-
phorylation appears to be mediated by
endogenous herpesviruses in this lym-
phoid tissue culture system, including
herpesviruses of relatively low pathogenic
potential (e.g., HHV-6) (Grivel et al., 2001;
Lisco et al., 2008). While studies of HIV
replication in isolated cell cultures are im-
portant for identifying many features ofCell Host & Microbe 4, SHIV replication and restriction, the study
by Lisco et al. (2008) reminds us that
coinfecting microbes may influence HIV
replication or disease, sometimes by to-
tally unexpected mechanisms (Stapleton
et al., 2004). Although this study does
not prove that the anti-HIV effect of acy-
clovir is responsible for decreased HIV
viral load or delayed HIV disease progres-
sion observed in acyclovir clinical studies
of HIV-infected people (Corey, 2007), it
provides an alternative hypothesis that,
as the authors suggest, deserves to be
tested by prospective clinical trials. Fu-
ture clinical studies should evaluate HIV
viral load reduction following acyclovir
therapy in the context of herpesvirus
infections other than HSV-2. Such studies
should determine if herpesviruses of
relatively low pathogenic potential are
capable of phosphorylating acyclovir in
a meaningful way in people with HIV
infection.
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